SCHEMBL987469

SCHEMBL987469

O=COC1CCC(CNC(=O)c2cc(Cl)cc3ccn(Cc4ccc5ccccc5n4)c23)CC1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACACB O00763 2/20 0.38
ACACA Q13085 2/20 0.38
RAB9A P51151 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
HDAC3 O15379 1/20 0.36
HDAC4 P56524 1/20 0.36
HDAC1 Q13547 1/20 0.36
HDAC7 Q8WUI4 1/20 0.36
HDAC2 Q92769 1/20 0.36
HDAC10 Q969S8 1/20 0.36
HDAC11 Q96DB2 1/20 0.36
HDAC8 Q9BY41 1/20 0.36
HDAC6 Q9UBN7 1/20 0.36
HDAC9 Q9UKV0 1/20 0.36
HDAC5 Q9UQL6 1/20 0.36
MCHR1 Q99705 1/20 0.35
HTR7 P34969 1/20 0.35
HTR4 Q13639 1/20 0.35
CHRM1 P11229 3/20 0.35
DRD2 P14416 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL988189 0.92 AR (0.37) ACACBACACARAB9ASMN1; SMN2HDAC3
SCHEMBL987962 0.91 HCRTR1 (0.40) ACACBACACAHDAC3HDAC4HDAC1
SCHEMBL987756 0.89 ACACB (0.35) ACACBACACAHDAC3HDAC4HDAC1
SCHEMBL988294 0.88 DRD2 (0.37) ACACBACACAHTR4CHRM1DRD2
SCHEMBL987467 0.87 ACACB (0.40) ACACBACACARAB9ASMN1; SMN2HDAC3
SCHEMBL27855437 0.87 ACACB (0.40) ACACBACACARAB9ASMN1; SMN2HDAC3
SCHEMBL12585664 0.87 ACACB (0.40) ACACBACACARAB9ASMN1; SMN2HDAC3
SCHEMBL12584399 0.87 ACACB (0.40) ACACBACACARAB9ASMN1; SMN2HDAC3
SCHEMBL12583946 0.87 ACACB (0.40) ACACBACACARAB9ASMN1; SMN2HDAC3
SCHEMBL985985 0.84 KLK1 (0.43) CHRM1DRD2DRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2565191-B1 4-(Indol-7-ylcarbonylaminomethyl)cyclohexanecarboxylic acid derivatives as EP4 receptor antagonists useful for the treatment of chronic renal failure or diabetic nephropathy ASTELLAS PHARMA INC (JP) 2014-10-08 EP disclosed
US-8598355-B2 Amide compound ASTELLAS PHARMA INC. (JP) 2013-12-03 US disclosed
EP-2565191-A1 4-(Indol-7-ylcarbonylaminomethyl)cyclohexanecarboxylic acid derivatives as EP4 receptor antagonists useful for the treatment of chronic renal failure or diabetic nephropathy Astellas Pharma Inc. (JP) 2013-03-06 EP disclosed
US-20110144153-A1 AMIDE COMPOUND ASTELLAS PHARMA INC. (JP) 2011-06-16 US disclosed
EP-2277858-A1 AMIDE COMPOUND Astellas Pharma Inc. (JP) 2011-01-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110144153-A1 AMIDE COMPOUND PTGER4, PTGER1, PTGER2 ACACB 870/4885ACACA 707/4885RAB9A 3160/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.